GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Summary
The purpose of this study is to compare genotype-guided dosing to standard of care in patients with colorectal and pancreatic cancer with UGT1AI intermediate or UGT1A usual genotypes.
Irinotecan is a chemotherapy drug that has been approved by the FDA to treat colorectal cancer. UGT1A1 is a germline marker for a liver enzyme that may predict irinotecan sensitivity.
This is a randomized trial, which means that patients will be randomly assigned (by chance) into one of the treatment groups.
General Information
NCT#: NCT05391126
Study ID: MCC-22-GI-125-PMC
Trial Phase: Phase I
Trial Sponsor: Reema A. Patel, University of Kentucky
Therapies Used in This Trial: Irinotecan